Do analysts prefer MGRX or BIAF?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mangoceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer MGRX or BIAF?

In the previous week, bioAffinity Technologies had 9 more articles in the media than Mangoceuticals. MarketBeat recorded 13 mentions for bioAffinity Technologies and 4 mentions for Mangoceuticals. Mangoceuticals' average media sentiment score of 0.72 beat bioAffinity Technologies' score of 0.34 indicating that Mangoceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mangoceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive bioAffinity Technologies 0 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer GXAI or BIAF?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gaxos.ai 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer GXAI or BIAF?

In the previous week, bioAffinity Technologies had 10 more articles in the media than Gaxos.ai. MarketBeat recorded 13 mentions for bioAffinity Technologies and 3 mentions for Gaxos.ai. Gaxos.ai's average media sentiment score of 0.93 beat bioAffinity Technologies' score of 0.34 indicating that Gaxos.ai is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gaxos.ai 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive bioAffinity Technologies 0 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend BMGL or BIAF?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, BMGL or BIAF?

Basel Medical Group has higher revenue and earnings than bioAffinity Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Basel Medical Group $8.90M 0.68 -$9.50M N/A N/A bioAffinity Technologies $5.85M 0.37 -$14.91M -$109.45 N/A

Does the media prefer BMGL or BIAF?

In the previous week, bioAffinity Technologies had 6 more articles in the media than Basel Medical Group. MarketBeat recorded 13 mentions for bioAffinity Technologies and 7 mentions for Basel Medical Group. Basel Medical Group's average media sentiment score of 0.43 beat bioAffinity Technologies' score of 0.34 indicating that Basel Medical Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Basel Medical Group 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral bioAffinity Technologies 0 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend AIDX or BIAF?

20/20 Biolabs currently has a consensus target price of $5.00, suggesting a potential upside of 1,497.44%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, research analysts clearly believe 20/20 Biolabs is more favorable than bioAffinity Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 20/20 Biolabs 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate BIAF or IVF?

INVO Fertility has a consensus price target of $20.00, suggesting a potential upside of 3,289.83%. Given INVO Fertility's stronger consensus rating and higher probable upside, analysts plainly believe INVO Fertility is more favorable than bioAffinity Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 INVO Fertility 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Does the media favor BIAF or IVF?

In the previous week, bioAffinity Technologies had 10 more articles in the media than INVO Fertility. MarketBeat recorded 13 mentions for bioAffinity Technologies and 3 mentions for INVO Fertility. INVO Fertility's average media sentiment score of 1.38 beat bioAffinity Technologies' score of 0.34 indicating that INVO Fertility is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment bioAffinity Technologies 0 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral INVO Fertility 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

bioAffinity Technologies (BIAF) Competitors

$3.56 -0.07 (-1.93%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$3.54 -0.02 (-0.70%)

As of 08:27 AM Eastern

Compare

BIAF vs. MGRX, GXAI, BMGL, AIDX, and IVF

Should you buy bioAffinity Technologies stock or one of its competitors? bioAffinity Technologies's main competitors and comparable companies include Mangoceuticals (MGRX), Gaxos.ai (GXAI), Basel Medical Group (BMGL), 20/20 Biolabs (AIDX), and INVO Fertility (IVF). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does bioAffinity Technologies compare to Mangoceuticals?

Mangoceuticals (NASDAQ:MGRX) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
bioAffinity Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

56.7% of Mangoceuticals shares are owned by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are owned by institutional investors. 16.0% of Mangoceuticals shares are owned by insiders. Comparatively, 2.7% of bioAffinity Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

bioAffinity Technologies has a net margin of -257.30% compared to Mangoceuticals' net margin of -4,794.60%. Mangoceuticals' return on equity of -96.39% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-4,794.60%	-96.39%	-89.60%
bioAffinity Technologies	-257.30%	-220.52%	-136.76%

Mangoceuticals has a beta of 1.98, indicating that its share price is 98% more volatile than the broader market. Comparatively, bioAffinity Technologies has a beta of -1.25, indicating that its share price is 225% less volatile than the broader market.

bioAffinity Technologies has higher revenue and earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mangoceuticals	$460K	15.36	-$20.64M	-$1.01	N/A
bioAffinity Technologies	$5.85M	0.37	-$14.91M	-$109.45	N/A

In the previous week, bioAffinity Technologies had 9 more articles in the media than Mangoceuticals. MarketBeat recorded 13 mentions for bioAffinity Technologies and 4 mentions for Mangoceuticals. Mangoceuticals' average media sentiment score of 0.72 beat bioAffinity Technologies' score of 0.34 indicating that Mangoceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mangoceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
bioAffinity Technologies	0 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Mangoceuticals beats bioAffinity Technologies on 8 of the 13 factors compared between the two stocks.

How does bioAffinity Technologies compare to Gaxos.ai?

Gaxos.ai (NASDAQ:GXAI) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

Gaxos.ai has a net margin of -64.81% compared to bioAffinity Technologies' net margin of -257.30%. Gaxos.ai's return on equity of -38.79% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gaxos.ai	-64.81%	-38.79%	-36.99%
bioAffinity Technologies	-257.30%	-220.52%	-136.76%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gaxos.ai	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
bioAffinity Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Gaxos.ai has higher earnings, but lower revenue than bioAffinity Technologies. Gaxos.ai is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gaxos.ai	$1.93M	2.58	-$3.90M	-$0.50	N/A
bioAffinity Technologies	$5.85M	0.37	-$14.91M	-$109.45	N/A

Gaxos.ai has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, bioAffinity Technologies has a beta of -1.25, indicating that its share price is 225% less volatile than the broader market.

In the previous week, bioAffinity Technologies had 10 more articles in the media than Gaxos.ai. MarketBeat recorded 13 mentions for bioAffinity Technologies and 3 mentions for Gaxos.ai. Gaxos.ai's average media sentiment score of 0.93 beat bioAffinity Technologies' score of 0.34 indicating that Gaxos.ai is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gaxos.ai	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
bioAffinity Technologies	0 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

42.6% of Gaxos.ai shares are held by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are held by institutional investors. 3.2% of Gaxos.ai shares are held by company insiders. Comparatively, 2.7% of bioAffinity Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Gaxos.ai beats bioAffinity Technologies on 10 of the 12 factors compared between the two stocks.

How does bioAffinity Technologies compare to Basel Medical Group?

Basel Medical Group (NASDAQ:BMGL) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, bioAffinity Technologies had 6 more articles in the media than Basel Medical Group. MarketBeat recorded 13 mentions for bioAffinity Technologies and 7 mentions for Basel Medical Group. Basel Medical Group's average media sentiment score of 0.43 beat bioAffinity Technologies' score of 0.34 indicating that Basel Medical Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Basel Medical Group	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
bioAffinity Technologies	0 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
bioAffinity Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Basel Medical Group has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market. Comparatively, bioAffinity Technologies has a beta of -1.25, suggesting that its share price is 225% less volatile than the broader market.

1.6% of bioAffinity Technologies shares are owned by institutional investors. 2.7% of bioAffinity Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Basel Medical Group has a net margin of 0.00% compared to bioAffinity Technologies' net margin of -257.30%. Basel Medical Group's return on equity of 0.00% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Basel Medical Group	N/A	N/A	N/A
bioAffinity Technologies	-257.30%	-220.52%	-136.76%

Basel Medical Group has higher revenue and earnings than bioAffinity Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Basel Medical Group	$8.90M	0.68	-$9.50M	N/A	N/A
bioAffinity Technologies	$5.85M	0.37	-$14.91M	-$109.45	N/A

Summary

Basel Medical Group beats bioAffinity Technologies on 8 of the 11 factors compared between the two stocks.

How does bioAffinity Technologies compare to 20/20 Biolabs?

20/20 Biolabs (NASDAQ:AIDX) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

In the previous week, bioAffinity Technologies had 12 more articles in the media than 20/20 Biolabs. MarketBeat recorded 13 mentions for bioAffinity Technologies and 1 mentions for 20/20 Biolabs. 20/20 Biolabs' average media sentiment score of 1.82 beat bioAffinity Technologies' score of 0.34 indicating that 20/20 Biolabs is being referred to more favorably in the media.

Company	Overall Sentiment
20/20 Biolabs	Very Positive
bioAffinity Technologies	Neutral

20/20 Biolabs has higher earnings, but lower revenue than bioAffinity Technologies. 20/20 Biolabs is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
20/20 Biolabs	$2.04M	1.96	-$3.74M	-$0.54	N/A
bioAffinity Technologies	$5.85M	0.37	-$14.91M	-$109.45	N/A

20/20 Biolabs currently has a consensus target price of $5.00, suggesting a potential upside of 1,497.44%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, research analysts clearly believe 20/20 Biolabs is more favorable than bioAffinity Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
bioAffinity Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

20/20 Biolabs has a net margin of 0.00% compared to bioAffinity Technologies' net margin of -257.30%. 20/20 Biolabs' return on equity of 0.00% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
20/20 Biolabs	N/A	N/A	N/A
bioAffinity Technologies	-257.30%	-220.52%	-136.76%

1.6% of bioAffinity Technologies shares are held by institutional investors. 29.8% of 20/20 Biolabs shares are held by company insiders. Comparatively, 2.7% of bioAffinity Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

20/20 Biolabs beats bioAffinity Technologies on 11 of the 15 factors compared between the two stocks.

How does bioAffinity Technologies compare to INVO Fertility?

bioAffinity Technologies (NASDAQ:BIAF) and INVO Fertility (NASDAQ:IVF) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

INVO Fertility has a consensus price target of $20.00, suggesting a potential upside of 3,289.83%. Given INVO Fertility's stronger consensus rating and higher probable upside, analysts plainly believe INVO Fertility is more favorable than bioAffinity Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
INVO Fertility	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

bioAffinity Technologies has higher earnings, but lower revenue than INVO Fertility. bioAffinity Technologies is trading at a lower price-to-earnings ratio than INVO Fertility, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
bioAffinity Technologies	$5.85M	0.37	-$14.91M	-$109.45	N/A
INVO Fertility	$6.84M	0.22	-$25.13M	-$33.83	N/A

INVO Fertility has a net margin of -116.29% compared to bioAffinity Technologies' net margin of -257.30%. INVO Fertility's return on equity of -85.54% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-257.30%	-220.52%	-136.76%
INVO Fertility	-116.29%	-85.54%	-31.05%

bioAffinity Technologies has a beta of -1.25, suggesting that its share price is 225% less volatile than the broader market. Comparatively, INVO Fertility has a beta of 2.39, suggesting that its share price is 139% more volatile than the broader market.

1.6% of bioAffinity Technologies shares are owned by institutional investors. Comparatively, 12.0% of INVO Fertility shares are owned by institutional investors. 2.7% of bioAffinity Technologies shares are owned by company insiders. Comparatively, 0.4% of INVO Fertility shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, bioAffinity Technologies had 10 more articles in the media than INVO Fertility. MarketBeat recorded 13 mentions for bioAffinity Technologies and 3 mentions for INVO Fertility. INVO Fertility's average media sentiment score of 1.38 beat bioAffinity Technologies' score of 0.34 indicating that INVO Fertility is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
bioAffinity Technologies	0 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
INVO Fertility	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

INVO Fertility beats bioAffinity Technologies on 12 of the 16 factors compared between the two stocks.

Get bioAffinity Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIAF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIAF vs. The Competition

Export

Metric	bioAffinity Technologies	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.18M	$10.03B	$7.19B	$13.18B
Dividend Yield	N/A	2.61%	2.52%	19.59%
P/E Ratio	-0.03	30.42	223.62	21.16
Price / Sales	0.37	4.67	547.34	66.59
Price / Cash	N/A	115.88	76.68	52.75
Price / Book	0.15	5.14	10.22	5.92
Net Income	-$14.91M	$315.68M	$3.50B	$380.90M
7 Day Performance	-36.88%	0.00%	-3.50%	-3.90%
1 Month Performance	-44.03%	-4.32%	-7.78%	-6.42%
1 Year Performance	-91.24%	9.31%	0.79%	-6.02%

bioAffinity Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIAF bioAffinity Technologies	0.2394 of 5 stars	$3.56 -1.9%	N/A	-91.8%	$2.18M	$5.85M	N/A	57	Gap Up
MGRX Mangoceuticals	1.1945 of 5 stars	$0.45 +7.7%	N/A	-87.5%	$9.02M	$315.23K	N/A	3	Positive News Gap Down
GXAI Gaxos.ai	1.0711 of 5 stars	$0.47 -4.3%	N/A	-76.6%	$5.23M	$1.93M	N/A	3	Short Interest Decrease
BMGL Basel Medical Group	0.6794 of 5 stars	$3.33 +5.0%	N/A	-79.6%	$5.02M	$14.55M	N/A	70
AIDX 20/20 Biolabs	2.4099 of 5 stars	$0.35 +0.0%	$5.00 +1,318.4%	N/A	$4.50M	$2.05M	N/A	14

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BIAF) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

bioAffinity Technologies (BIAF) Competitors

BIAF vs. MGRX, GXAI, BMGL, AIDX, and IVF

How does bioAffinity Technologies compare to Mangoceuticals?

Summary

How does bioAffinity Technologies compare to Gaxos.ai?

Summary

How does bioAffinity Technologies compare to Basel Medical Group?

Summary

How does bioAffinity Technologies compare to 20/20 Biolabs?

Summary

How does bioAffinity Technologies compare to INVO Fertility?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIAF vs. The Competition

bioAffinity Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

bioAffinity Technologies (BIAF) Competitors

BIAF vs. MGRX, GXAI, BMGL, AIDX, and IVF

How does bioAffinity Technologies compare to Mangoceuticals?

Do analysts prefer MGRX or BIAF?

Do insiders and institutionals have more ownership in MGRX or BIAF?

Is MGRX or BIAF more profitable?

Which has more volatility and risk, MGRX or BIAF?

Which has stronger valuation and earnings, MGRX or BIAF?

Does the media prefer MGRX or BIAF?

Summary

How does bioAffinity Technologies compare to Gaxos.ai?

Is GXAI or BIAF more profitable?

Do analysts prefer GXAI or BIAF?

Which has stronger valuation & earnings, GXAI or BIAF?

Which has more risk & volatility, GXAI or BIAF?

Does the media prefer GXAI or BIAF?

Do institutionals & insiders believe in GXAI or BIAF?

Summary

How does bioAffinity Technologies compare to Basel Medical Group?

Does the media prefer BMGL or BIAF?

Do analysts recommend BMGL or BIAF?

Which has more risk & volatility, BMGL or BIAF?

Do insiders and institutionals have more ownership in BMGL or BIAF?

Is BMGL or BIAF more profitable?

Which has better valuation and earnings, BMGL or BIAF?

Summary

How does bioAffinity Technologies compare to 20/20 Biolabs?

Does the media prefer AIDX or BIAF?

Which has higher valuation & earnings, AIDX or BIAF?

Do analysts recommend AIDX or BIAF?

Is AIDX or BIAF more profitable?

Do insiders and institutionals hold more shares of AIDX or BIAF?

Summary

How does bioAffinity Technologies compare to INVO Fertility?

Do analysts rate BIAF or IVF?

Which has stronger valuation and earnings, BIAF or IVF?

Is BIAF or IVF more profitable?

Which has more volatility & risk, BIAF or IVF?

Do institutionals and insiders have more ownership in BIAF or IVF?

Does the media favor BIAF or IVF?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIAF vs. The Competition

bioAffinity Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools